A Word From The Writing Team (September 2018)

This issue includes: Boost Your Communication Skills with Nature Win a Prize for Writing About Health Car

A Word From The Writing Team (January 2019)

This issue includes: Grammarly Tips Expanded NVivo Access Upcoming Workshop

A Word From The Writing Team (March 2019)

This issue includes: Key to Great Writing: Rewriting 3-Minute Thesis Competition (3MT) Upcoming Workshop

A Word From The Writing Team (October 2018)

This issue includes: Writing Lessons from Ted-Ed WHYY\u27s Maiken Scott on Communicating Science Paywall: The Business of Scholarshi

A Word From The Writing Team (July 2018)

This issue includes: From Thesis to Journal Article Open All Summer Sign Up for Our Fall Writing Retreat Writing Caf

A Word From The Writing Team (November 2018)

This issue includes: New! Open Access Funds Available January Writing Retreat A Thanksgiving Though

A Word From The Writing Team (December 2018)

This issue includes: January Writing Retreat Find the Time Worksho

Chronic cannabinoid exposure reduces phencyclidine-induced schizophrenia-like positive symptoms in adult rats

Rationale: Chronic cannabis use can induce psychotic states that resemble schizophrenia. Yet, schizophrenic patients often smoke cannabis as a form of self-medication to counter the aversive symptoms of schizophrenia. We recently demonstrated an ameliorating effect of cannabinoid self-administration (SA) on negative and cognitive schizophrenia-like symptoms induced experimentally by the non-competitive N-methyl-d-aspartate receptor antagonist phencyclidine (PCP). Whether cannabinoid SA alleviates or exacerbates schizophrenia-like positive symptoms is still unclear. Objectives: This follow-up study aimed to evaluate the effect of self-administered cannabinoid on PCP-induced schizotypic positive symptoms in adult rats. Methods: Male rats were trained to self-administer either the cannabinoid CB1 receptor agonist WIN 55,212-2 (WIN; 12.5 μg/kg/infusion) or its vehicle (Veh) intravenously. The effects of acute and chronic intermittent intraperitoneal administration of PCP (2.5 mg/kg) on motor parameters were then tested in Veh-SA and WIN-SA. Results: Cannabinoid SA significantly attenuated the psychotomimetic effects of PCP exposure observed in control rats. Following acute PCP administration, WIN-SA animals displayed more frequent rearing and lower anxiety-like profile than Veh-SA rats. WIN-SA rats also exhibited lower behavioural sensitisation to chronic PCP treatment as demonstrated by reduced hyperlocomotion in response to an acute PCP challenge. In addition, parallel experiments performed in experimenter-administered rats that received WIN at comparable SA doses confirmed the ameliorating effects of cannabinoid exposure on PCP-induced schizotypic behaviours, indicating that motivational effects were not responsible for the ameliorative effects of cannabinoids. Conclusions: Our results indicate that cannabis may exert protective effects on positive schizotypic symptoms in adult animals such as hypermotility and anxiety state